Remember Episode 12, where we reviewed a Houston paper on DSD that showed worse outcomes with DSD? At the end of that pod, I spoke about an ongoing RCT trial comparing DSD to standard therapy AND vector change defibrillation. Well, the pilot phase of that trial is over and has JUST been published. It has some surprising preliminary results. Join us and find out how that study is going. If you like what you hear, please give us a 5-star rating on Apple Podcasts and other premier podcast purveyors and tell your friends to subscribe.

The final part of our coverage of some of the research from NAEMSP2020 in San Diego. If you missed any of the first three episodes, download them and listen. They were great! In this episode, we wrap up the series with outstanding discussions. We discuss the epidemiology of pediatric trauma activations with San Antonio’s Dr. Craig Cooley and finish up with a discussion with Dr. Henry Wang. Dr. Wang talks to us through an oral abstract he presented here on a secondary analysis looking at the impact of FPS in the PART trial comparing ET and King LT in cardiac arrest. As a bonus, he talked us through the original PART trial, where he was the principal investigator. As always, we want to hear your feedback. Let us know what you think: @DrJeffJarvis and @EMSLigthouse. Subscribe and give us an excellent rating on Apple Podcast.

And…we are back for part 3 of our coverage of some of the research from NAEMSP2020 in San Diego. If you missed parts 1 or 2, be sure to download them and listen. They were great! In this episode, we have two great interviews. We talk with Dr. Veer Vithalani of MedStar in Fort Worth, TX, about his work using EtCO2 to detect unrecognized BVM ventilation failures. We also chat with Drs. Casey Patrick and Rob Dickson from Montgomery County Hospital District EMS in Conroe, TX, about push-dose drugs, including epinephrine and nitroglycerin.

What if we told you that neither amiodarone nor lidocaine did any better in cardiac arrest when given by IO? What if we told you neither one improved survival when given by IV? Would you think I was smoking crack? Yeah, I would have thought that, too, until last week. I will quickly recap this important secondary analysis of the ALPS trial. As always, please subscribe and give us a 5-star rating on Apple Podcasts. We’d love to hear your thoughts, questions, and suggestions. Join us on Twitter: @DrJeffJarvis, @EMSLighthouse, @FlightBridgeED

And we’re back for part 2 of our coverage of some of the research from NAEMSP2020 in San Diego. If you missed part 1, be sure to download it and listen. It was great! As always, we want to hear your feedback. Let us know what you think: @DrJeffJarvis and @EMSLightouse. Subscribe and give us an excellent rating on Apple Podcast.

Did y’all make it to NAEMSP 2020 in San Diego? If not, I’m sorry. It was awesome! If you did, you probably had a great time but still missed a lot. There’s just too much going on. Being the research nerds we are, we focused our time on the oral and poster presentations. We interviewed as many investigators as we could. In fact, we recorded more audio than we could fit in one episode. So… we’re cutting them into smaller chunks and will get them out faster than our regular every two-week release schedule. Join us as we sit down (or stand up, as the case may be) for some great interviews from NAEMSP. As always, we want to hear your feedback. Let us know what you think: @DrJeffJarvis and @EMSLightouse. Subscribe and give us an excellent rating on Apple Podcast.

HAPPY NEW YEARS! We hope you are celebrating 2020 at the NAEMSP National Conference in San Diego. In this special episode of the EMS Collaborative, we discuss the wonderful world of Mobile Integrated Health (MIH) and ET3. It's a fascinating conversation filled with MIH history, MIH research, editorials, and, of course, checking to see if Dr. Sahni can qualify for Medicare. Check out this fun, entertaining, and witty podcast today! As always, THANK YOU for listening! Hawnwan Philip Moy MD (@pecpodcast), Scott Goldberg MD, MPH (@EMS_Boston), Jeremiah Escajeda MD, MPH (@jerescajeda), Joelle Donofrio-Odmann DO (@PEMems), Mike Verkest (@MikeVerkest), Ritu Sahni MD (@MD59), Jeffrey Jarvis MD (@DrJeffJarvis), and @FlightBridgeED!

Dr. Jarvis had an opportunity to sit with Dr. Ben Bobrow at the Texas EMS Conference. Dr. Bobrow is the chair of Emergency Medicine at UT Houston. During his time in Arizona, Dr. Bobrow was instrumental in studying Traumatic Brain Injury and approaches to improved outcomes in cardiac arrest. If you know about the dangers of hypoxia and hypotension in TBI or the importance of minimally interrupted chest compressions and passive oxygenation in cardiac arrest, you should hear this interview. If you like what you hear, please give us a 5-star rating on Apple Podcasts and other premier podcast purveyors and tell your friends to subscribe.

The debate has raged. In this corner, we have our established champion succinylcholine, or, as the oldsters call it, “because we’ve always done it this way.” In that other corner, we have the brash newcomer, rocuronium, or, as the youngsters call it, “OMG… what about the hyperK!.” Wouldn’t you just like an answer? Which is better? SAMU to the (potential) rescue. Our French colleagues published a Randomized Clinical Trial comparing FPS among pre-hospital patients undergoing intubation between succinylcholine and rocuronium. What did they find? Join Dr. Jarvis for a hot-off-the-presses podcast that will give you the down-and-dirty about this trial ON THE DAY IT WAS PUBLISHED! Take THAT Second Shift! If you like what you hear, please give us a 5-star rating on Apple Podcasts and tell your friends to subscribe. As always, we want to hear your feedback. You can reach us on Twitter at @EMSLighthouse and @DrJeffJarvis.

Should we chill out with the non-shockable cardiac arrests? Another look at targeted temperature management. First, we knew early hypothermia after ROSC saved brains. Then, we learned that doing it in the field didn’t make a difference and that there was no difference between 33C and 36C. This month, the NEJM published the HYPERION trial of non-shockable arrests randomized to hypothermia (33C) or normothermia (37C). If you like what you hear, please give us a 5-star rating on Apple Podcasts and other premier podcast purveyors and tell your friends to subscribe.